• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Herpes Simplex Infections - Pipeline Review, H2 2012 Product Image

Herpes Simplex Infections - Pipeline Review, H2 2012

  • Published: September 2012
  • 137 pages
  • Global Markets Direct

Herpes Simplex Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Herpes Simplex Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Herpes Simplex Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections. Herpes Simplex Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Herpes Simplex Infections.
- A review of the Herpes Simplex Infections products under READ MORE >

2
List of Tables 8
List of Figures 9
Introduction 10
REPORT COVERAGE 10
Herpes Simplex Infections Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Herpes Simplex Infections 12
Herpes Simplex Infections Therapeutics under Development by Companies 14
Herpes Simplex Infections Therapeutics under Investigation by Universities/Institutes 18
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Comparative Analysis 21
Discovery and Pre-Clinical Stage Products 22
Comparative Analysis 22
Herpes Simplex Infections Therapeutics – Products under Development by Companies 23
Herpes Simplex Infections Therapeutics – Products under Investigation by Universities/Institutes 24
Companies Involved in Herpes Simplex Infections Therapeutics Development 25
Vical Incorporated 25
Antigenics, Inc. 26
GenVec, Inc. 27
Novartis AG 28
CEL-SCI Corporation 29
Mymetics Corporation 30
NanoViricides, Inc. 31
Nutra Pharma Corporation 32
Peregrine Pharmaceuticals, Inc. 33
CytoGenix, Inc. 34
Alnylam Pharmaceuticals, Inc 35
Flamel Technologies S.A. 36
Starpharma Holdings Limited 37
Summit Corporation plc 38
BioAlliance Pharma SA 39
Oryzon 40
Functional Genetics, Inc. 41
Colby Pharmaceutical Company 42
Osel Inc. 43
AiCuris GmbH & Co. KG 44
Asahi Kasei Pharma 45
AlphaVax, Inc. 46
Nitric Biotherapeutics, Inc. 47
Romark Laboratories, L.C. 48
Chimerix, Inc. 49
Lumavita AG 50
NanoBio Corporation 51
PharmaNova Inc. 52
Immune Design Inc. 53
Redox Pharmaceutical Corporation 54
PepTcell Limited 55
Genocea Biosciences, Inc. 56
Beech Tree Labs, Inc. 57
EMS S.A. 58
Herpes Simplex Infections – Therapeutics Assessment 59
Assessment by Monotherapy Products 59
Assessment by Combination Products 60
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 66
tenofovir - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
acyclovir - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
RPI-78M - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
RPI-MN - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
famciclovir - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
simplivir - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
CEL-1000 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
doxorubicin - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
HSV Vaccine - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
NB-001 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
LMV-601 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
HSV-2 Vaccine - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
HSV-2 Vaccine - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
HerpV Vaccine - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
AIC-316 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
acyclovir - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
valacyclovir hydrochloride - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
SPL-7013 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
acyclovir CR - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
valacyclovir hydrochloride - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
RNAi Therapeutic For HSV Infection - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
BTL-TML-HSV - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
acyclovir - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Antiviral Program - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
MucoCept Platform - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
GEN-003 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
HSV-2 Px - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
penciclovir - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
famciclovir - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
famciclovir - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
JVRS-100 + HSV-2 Vaccine - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
New Thiazolides - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
Drug For Herpes Simplex - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
PGN-632 - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
ID-G103 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
PN 200 - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
LSD1 Inhibitor For HSV - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
PN 201 - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
Valacyclovir - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
HSV Program - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
HerpeCide-I - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
Herpes Simplex Infections Therapeutics – Drug Profile Updates 117
Herpes Simplex Infections Therapeutics – Discontinued Products 128
Herpes Simplex Infections Therapeutics - Dormant Products 129
Herpes Simplex Infections – Product Development Milestones 130
Featured News & Press Releases 130
Aug 15, 2012: Genocea Initiates Phase I/IIa Study With Therapeutic Vaccine Candidate For Herpes Simplex Virus-2 Infection 130
Aug 07, 2012: AiCuris To Present Data On AIC316 At International Herpesvirus Workshop 130
Jul 26, 2012: BioAlliance Pharma Receives US Patent Covering Sitavig 131
May 29, 2012: BioAlliance Announces Receivability Of Sitavig US Registration Dossier 131
May 22, 2012: Vical Publishes Preclinical Results Of Herpes Simplex Vaccine In Journal Of General Virology 132
May 16, 2012: Vical Presents Update On Herpes Simplex Vaccine Development At ASGCT Conference 132
May 04, 2012: Genocea Highlights Key Progress In Development Of First Vaccine Candidate, Targeting HSV-2 133
Apr 16, 2012: AiCuris To Report AIC316 Phase II trial Data At International Meetings 134
Oct 05, 2011: BioAlliance Submits Sitavir European Registration Dossier Through European Decentralized Procedure 134
Oct 03, 2011: Vical Reports Prophylactic And Therapeutic Efficacy With Herpes Simplex Vaccines In Guinea Pig Model 135
Appendix 136
Methodology 136
Coverage 136
Secondary Research 136
Primary Research 136
Expert Panel Validation 136
Contact Us 137
Disclaimer 137

List of Tables
Number of Products Under Development for Herpes Simplex Infections, H2 2012 12
Products under Development for Herpes Simplex Infections – Comparative Analysis, H2 2012 13
Number of Products under Development by Companies, H2 2012 15
Number of Products under Development by Companies, H2 2012 (Contd..1) 16
Number of Products under Development by Companies, H2 2012 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H2 2012 18
Comparative Analysis by Late Stage Development, H2 2012 19
Comparative Analysis by Mid Clinical Stage Development, H2 2012 20
Comparative Analysis by Early Clinical Stage Development, H2 2012 21
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 22
Products under Development by Companies, H2 2012 23
Products under Investigation by Universities/Institutes, H2 2012 24
Vical Incorporated, H2 2012 25
Antigenics, Inc., H2 2012 26
GenVec, Inc., H2 2012 27
Novartis AG, H2 2012 28
CEL-SCI Corporation, H2 2012 29
Mymetics Corporation, H2 2012 30
NanoViricides, Inc., H2 2012 31
Nutra Pharma Corporation, H2 2012 32
Peregrine Pharmaceuticals, Inc., H2 2012 33
CytoGenix, Inc., H2 2012 34
Alnylam Pharmaceuticals, Inc, H2 2012 35
Flamel Technologies S.A., H2 2012 36
Starpharma Holdings Limited, H2 2012 37
Summit Corporation plc, H2 2012 38
BioAlliance Pharma SA, H2 2012 39
Oryzon, H2 2012 40
Functional Genetics, Inc., H2 2012 41
Colby Pharmaceutical Company, H2 2012 42
Osel Inc., H2 2012 43
AiCuris GmbH & Co. KG, H2 2012 44
Asahi Kasei Pharma, H2 2012 45
AlphaVax, Inc., H2 2012 46
Nitric Biotherapeutics, Inc., H2 2012 47
Romark Laboratories, L.C., H2 2012 48
Chimerix, Inc., H2 2012 49
Lumavita AG, H2 2012 50
NanoBio Corporation, H2 2012 51
PharmaNova Inc., H2 2012 52
Immune Design Inc., H2 2012 53
Redox Pharmaceutical Corporation, H2 2012 54
PepTcell Limited, H2 2012 55
Genocea Biosciences, Inc., H2 2012 56
Beech Tree Labs, Inc., H2 2012 57
EMS S.A., H2 2012 58
Assessment by Monotherapy Products, H2 2012 59
Assessment by Combination Products, H2 2012 60
Assessment by Stage and Route of Administration, H2 2012 62
Assessment by Stage and Molecule Type, H2 2012 65
Herpes Simplex Infections Therapeutics – Drug Profile Updates 117
Herpes Simplex Infections Therapeutics – Discontinued Products 128
Herpes Simplex Infections Therapeutics – Dormant Products 129

List of Figures
Number of Products under Development for Herpes Simplex Infections, H2 2012 12
Products under Development for Herpes Simplex Infections – Comparative Analysis, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 18
Late Stage Products, H2 2012 19
Mid Clinical Stage Products, H2 2012 20
Early Clinical Stage Products, H2 2012 21
Discovery and Pre-Clinical Stage Products, H2 2012 22
Assessment by Monotherapy Products, H2 2012 59
Assessment by Combination Products, H2 2012 60
Assessment by Route of Administration, H2 2012 61
Assessment by Stage and Route of Administration, H2 2012 62
Assessment by Molecule Type, H2 2012 63
Assessment by Stage and Molecule Type, H2 2012 64

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos